Everett Meyer: Clinical Trials

4 trials sponsored by Everett Meyer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated, 1 unknown, 1 withdrawn. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Terminated 1, Unknown 1, Withdrawn 1
Phase 22Completed 1, Terminated 1

Follow Everett Meyer: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
donor regulatory T lymphocytes, laboratory biomarker analysis - Graft Versus Host Disease
Phase 1WithdrawnEverett Meyer2015-08-062023-11-22
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
CIK cells, Cyclosporine, Mycophenolate Mofetil - Neural Tube Defects, Anemia
Phase 2CompletedEverett Meyer442011-03-012019-05-07
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
Immune Tolerance - ESRD
Phase 1UnknownEverett Meyer252010-07-142023-06-18
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Regulatory T-cells, Conventional T-cells, Melphalan - Leukemia, Acute, Chronic Myelogenous Leukemia (CML)
Phase 1 / Phase 2TerminatedEverett Meyer102009-06-012018-06-27

Conditions studied

Myelodysplastic Syndromes (2)  ·  Anemia (1)  ·  Graft vs Host Disease (1)  ·  Kidney Failure, Chronic (1)  ·  Leukemia (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Myeloproliferative Disorders (1)  ·  Neural Tube Defects (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Interventions

Antilymphocyte Serum (2)  ·  thymoglobulin (2)  ·  Cyclosporine (1)  ·  Immune Tolerance (1)  ·  Kidney Transplantation (1)  ·  Melphalan (1)  ·  Mycophenolic Acid (1)  ·  Thiotepa (1)

Countries

United States (4)

Top investigators

Everett H Meyer, MD, PhD (1)  ·  Stephan Busque, MD,MS (1)

Results publications

PMID 30951840, PMID 34432869

NIH funding

P01HL075462 (1)